Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use...

Area of Science:

• Aesthetic Medicine
• Dermatology
• Neurology

Background:

• RelabotulinumtoxinA (relaBoNT-A) is a novel, ready-to-use liquid formulation of botulinum toxin A.
• It utilizes PEARL technology for a highly effective, complex-free product.

Purpose of the Study:

• To report subject-assessed effectiveness and satisfaction outcomes from the phase 3 READY-1 study of relaBoNT-A.
• Evaluate patient-reported improvements in glabellar lines and overall satisfaction.

Main Methods:

• Adults with moderate-to-severe glabellar lines were randomized to receive relaBoNT-A (50 U) or placebo.
• A 6-month, double-blind, multicenter study assessed subject-reported endpoints including glabellar line severity (GL-SLA) and aesthetic improvement (GAIS).
• Patient satisfaction and well-being were evaluated using validated questionnaires (FLTSQ, Natural Expressions, FACE-Q).

Main Results:

• RelaBoNT-A showed significantly higher responder rates for GL-SLA improvement compared to placebo at all time points up to 6 months (P<0.001).
• High GAIS responder rates were observed with relaBoNT-A (74.3-98.1%) versus placebo (9.0-16.2%).
• Patients treated with relaBoNT-A reported significantly higher satisfaction, natural-looking results, confidence in facial expressions, and improved psychological well-being.

Conclusions:

• A single treatment with relaBoNT-A led to significant and sustained improvements in glabellar line severity over 6 months.
• RelaBoNT-A demonstrated efficacy in providing natural-looking results, high patient satisfaction, and enhanced psychological well-being.